Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lacticaseibacillus casei LC2W
- Development stage
- Preclinical
- Lead developer
- Bright Dairy
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lacticaseibacillus casei LC2W (L.casei LC2W) is a proprietary probiotic strain developed by Bright Dairy & Food Co., Ltd. [4, 6] It is a live biotherapeutic product being investigated for its health benefits. Clinical studies have shown that oral administration of L.casei LC2W can provide significant benefits for weight control, glucose and lipid metabolism, and reduce inflammatory and oxidative stress parameters. [1, 6] The mechanism is believed to involve modulating the gut microbiota, which in turn ameliorates gut inflammation and promotes glucose and lipid degradation pathways. [1, 6] For instance, it has been shown to enrich the abundance of beneficial bacteria like Lacticaseibacillus and Bifidobacterium. [1, 6] The strain has also demonstrated potential in preventing colitis, inhibiting the colonization of pathogenic bacteria like E. coli O157:H7, and exhibiting anti-hypertensive bioactivity. [1, 8, 12] Bright Dairy incorporates this strain into some of its yogurt products. [3, 4, 5]
- Other names
- L.casei LC2W干酪乳杆菌LC2W
Beyond the preview
Go deeper on lacticaseibacillus casei LC2W.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lacticaseibacillus casei LC2W.